We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+8.25%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
Cap. Flow
+$308M
Cap. Flow %
18.12%
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$40.1M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$37.1M
3
DNLI icon
Denali Therapeutics
DNLI
+$36.2M
4
INSP icon
Inspire Medical Systems
INSP
+$27.3M
5
VIR icon
Vir Biotechnology
VIR
+$21.9M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$39.4M
2
RAPT
RAPT Therapeutics
RAPT
+$17.3M
3
CDTX
Cidara Therapeutics
CDTX
+$13.2M
4
FULC icon
Fulcrum Therapeutics
FULC
+$10.4M
5
ABUS icon
Arbutus Biopharma
ABUS
+$9.98M

Sector Composition

Rank Sector Weight
1 Healthcare 88.42%
2 Miscellaneous 9.68%
3 Financials 1.51%
4 Technology 0.08%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITGR icon
176
Integer Holdings
ITGR
$4.26B
$770K 0.05%
+8,750
New +$745K
REPL icon
177
CALL
Replimune Group
REPL
$1.46B
$765K 0.05%
100,000
+75,000
+300% +$573K
KPTI icon
178
Karyopharm Therapeutics
KPTI
$42.4M
$762K 0.04%
136,736
+86,736
+173% +$661K
CMPX icon
179
Compass Therapeutics
CMPX
$432M
$735K 0.04%
139,000
– –
NUVL
180
DELISTED
Nuvalent
NUVL
$711K 0.04%
6,942
+100
+1% +$10.2K
CGEM icon
181
Cullinan Oncology
CGEM
$1.4B
$711K 0.04%
50,000
– –
IDYA icon
182
IDEAYA Biosciences
IDYA
$3.87B
$666K 0.04%
20,000
– –
GUTS icon
183
CALL
Fractyl Health
GUTS
$105M
$654K 0.04%
1,428,571
– –
ENTA icon
184
Enanta Pharmaceuticals
ENTA
$396M
$649K 0.04%
51,357
+10,000
+24% +$134K
VERA icon
185
Vera Therapeutics
VERA
$2.46B
$645K 0.04%
16,033
+1,300
+9% +$56K
YARW
186
Yarrow Bioscience
YARW
$98.8M
$636K 0.04%
21,278
+16,202
+319% +$473K
BSX icon
187
Boston Scientific
BSX
$67.9B
$628K 0.04%
10,000
+5,000
+100% +$400K
AVTR icon
188
Avantor
AVTR
$9.86B
$627K 0.04%
80,000
+10,000
+14% +$98.4K
ARVN icon
189
Arvinas
ARVN
$600M
$610K 0.04%
57,591
-500
-0.9% -$6.19K
KZR
190
DELISTED
Kezar Life Sciences
KZR
$608K 0.04%
81,933
-35,507
-30% -$231K
KLRS
191
Kalaris Therapeutics
KLRS
$95.9M
$577K 0.03%
100,000
– –
MIRM icon
192
Mirum Pharmaceuticals
MIRM
$5.94B
$573K 0.03%
+6,200
New +$583K
JAZZ icon
193
Jazz Pharmaceuticals
JAZZ
$15.9B
$567K 0.03%
3,000
-5,000
-63% -$874K
ASMB icon
194
Assembly Biosciences
ASMB
$694M
$554K 0.03%
19,947
+200
+1% +$5.71K
PRLD icon
195
Prelude Therapeutics
PRLD
$437M
$523K 0.03%
+152,825
New +$401K
GTERU
196
Globa Terra Acquisition Corp Units
GTERU
$518K 0.03%
50,000
– –
USFR icon
197
WisdomTree Floating Rate Treasury Fund
USFR
$18.7B
$503K 0.03%
10,000
– –
ACRS icon
198
Aclaris Therapeutics
ACRS
$885M
$497K 0.03%
132,426
-481,560
-78% -$1.62M
PRAX icon
199
Praxis Precision Medicines
PRAX
$9.63B
$483K 0.03%
1,500
– –
LUNG icon
200
Pulmonx
LUNG
$102M
$483K 0.03%
374,497
+19,087
+5% +$31.5K
6 7
8
9 10

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, ADAR1 Capital Management held 351 positions worth $1.7B, up 25% from $1.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

ADAR1 Capital Management deployed $308M of net new capital in Q1 2026, opening 78 new positions and adding to 102 existing holdings. Its largest new stake was Beam Therapeutics: 1,446,375 shares worth $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $10.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2026 buy was Beam Therapeutics: 1,446,375 shares worth $34.5M.
  • ADAR1 Capital Management added most to Crinetics Pharmaceuticals in Q1 2026, an estimated $37.1M increase.
  • ADAR1 Capital Management's biggest Q1 2026 reduction was Fulcrum Therapeutics, cutting an estimated $10.4M.
  • ADAR1 Capital Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $39.4M.
  • ADAR1 Capital Management's ten largest holdings make up 40% of its $1.7B portfolio in Q1 2026.
  • ADAR1 Capital Management opened 78 new positions and closed 41 in Q1 2026.
  • ADAR1 Capital Management's portfolio value rose 25% quarter-over-quarter to $1.7B.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.